Cardlytics, Inc.
DE ˙ DB ˙ US14161W1053
0,45 € ↓ -0,04 (-8,23%)
2026-06-05
DEL PRIS
SecurityDE:CYX / Cardlytics, Inc.
InstitutionSummit Financial Strategies, Inc.
Latest Disclosed Ownership14,000 shares
Latest Disclosed Value $ 14,700
Summit Financial Strategies, Inc. ownership in CYX / Cardlytics, Inc.

On May 1, 2026 - Summit Financial Strategies, Inc. filed a 13F-HR form disclosing ownership of 14,000 shares of Cardlytics, Inc. (DE:CYX) valued at $10,368 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 27, 2026 disclosing 14,000 shares of Cardlytics, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $6,244 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-01 2026-03-31 13F CARDLYTICS COM 14161W105 14,000 0 0.00 15 -12.50 0.0012
2026-01-27 2025-12-31 13F CARDLYTICS COM 14161W105 14,000 0 0.00 16 -52.94 0.0013
2025-10-22 2025-09-30 13F CARDLYTICS COM 14161W105 14,000 0 0.00 34 47.83 0.0029
2025-07-17 2025-06-30 13F CARDLYTICS COM 14161W105 14,000 0 0.00 23 -8.00 0.0021
2025-05-12 2025-03-31 13F CARDLYTICS COM 14161W105 14,000 0 0.00 25 -50.98 0.0026
2025-01-22 2024-12-31 13F CARDLYTICS COM 14161W105 14,000 0 0.00 52 15.91 0.0057
2024-10-16 2024-09-30 13F CARDLYTICS COM 14161W105 14,000 0 0.00 45 -61.40 0.0050
2024-07-19 2024-06-30 13F CARDLYTICS COM 14161W105 14,000 0 0.00 115 -43.56 0.0143
2024-05-09 2024-03-31 13F CARDLYTICS COM 14161W105 14,000 0 0.00 203 57.81 0.0283
2024-02-13 2023-12-31 13F CARDLYTICS COM 14161W105 14,000 0 0.00 129 -44.59 0.0197
2023-10-24 2023-09-30 13F CARDLYTICS COM 14161W105 14,000 0 0.00 231 162.50 0.0440
2023-07-21 2023-06-30 13F CARDLYTICS COM 14161W105 14,000 0 0.00 88 87.23 0.0165
2023-04-21 2023-03-31 13F CARDLYTICS COM 14161W105 14,000 14,000 48 0.0094
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.